SUBSEQUENT EVENT (Details Narrative) $ / shares in Units, ¥ in Millions |
1 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Jan. 26, 2026 |
Jan. 09, 2026
$ / shares
shares
|
Oct. 27, 2025 |
Jul. 03, 2025
USD ($)
|
Oct. 27, 2025 |
Dec. 10, 2025
CNY (¥)
|
May 06, 2025
$ / shares
|
Mar. 31, 2025
$ / shares
shares
|
Dec. 31, 2024
$ / shares
shares
|
|
| Subsequent Event [Line Items] | |||||||||
| Common stock, par value | $ / shares | $ 0.0005 | $ 0.0005 | |||||||
| Reverse stock split | 1-for-10 | ||||||||
| Common stock, shares issued | 1,382,114 | 1,120,145 | |||||||
| Forecast [Member] | Private Placement Agreements [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Sale of stock description of transaction | On January 26, 2026, March 5, 2026, March 19, 2026 and March 28, 2026, respectively, the Company entered into equity financing agreements (individually the “Private Placement Agreement”; collectively the “Private Placement Agreements”), with four individual investors (individually the “Private Placement Purchaser”; collectively “Private Placement Purchasers”), pursuant to which the Company agreed to issue new shares of common stock to such investors that in aggregate accounted for approximately 18% of the total shares issued and outstanding of the Company as of December 31, 2025. The purchase price per share under the Private Placement Agreement dated January 26, 2026, was set at 90% of the average closing price of the Company’s common stock for the five trading days prior to the date of such agreement, while the purchase prices under the Private Placement Agreements executed in March 2026 were set at 85% of, or 15% off, the closing price of the Company’s common stock on the trading day immediately preceding the respective agreement dates, as quoted on the Nasdaq Stock Market. | ||||||||
| Forecast [Member] | 2019 Stock Incentive Plan [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Reverse stock split | 10-to-1 | ||||||||
| Shandong Rongyuan Pharmaceutical Co Ltd [Member] | Forecast [Member] | 2019 Stock Incentive Plan [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Common stock, par value | $ / shares | $ 0.0005 | ||||||||
| Common stock, shares issued | 103,378 | ||||||||
| Shandong Rongyuan Pharmaceutical Co Ltd [Member] | Forecast [Member] | 2025 Stock Incentive Plan [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Common stock, shares issued | 200,000 | ||||||||
| Common Stock [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Common stock, shares issued | 1,120,145 | ||||||||
| Subsequent Event [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Common stock, par value | $ / shares | $ 0.0005 | ||||||||
| Reverse stock split | 1-for-10 | ||||||||
| Subsequent Event [Member] | Shandong Rongyuan Pharmaceutical Co Ltd [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Equity interest rate | 100.00% | ||||||||
| Aggregate consideration cost | ¥ | ¥ 21.2 | ||||||||
| Subsequent Event [Member] | Common Stock [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Covering value | $ | $ 10,000,000 | ||||||||
| Subsequent Event [Member] | Preferred Stock [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Covering value | $ | 10,000,000 | ||||||||
| Subsequent Event [Member] | Warrant [Member] | |||||||||
| Subsequent Event [Line Items] | |||||||||
| Covering value | $ | $ 10,000,000 |